TY - JOUR
T1 - Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection
AU - Berretta, Massimiliano
AU - Lleshi, Arben
AU - Cappellani, Alessandro
AU - Bearz, Alessandra
AU - Spina, Michele
AU - Talamini, Renato
AU - Cacopardo, Bruno
AU - Nunnari, Giuseppe
AU - Montesarchio, Vincenzo
AU - Izzi, Immacolata
AU - Lanzafame, Massimiliano
AU - Nasti, Guglielmo
AU - Basile, Francesco
AU - Berretta, Salvatore
AU - Fisichella, Rossella
AU - Schiantarelli, Clara C.
AU - Garlassi, Elisa
AU - Ridolfo, Annalisa
AU - Guella, Lorenza
AU - Tirelli, Umberto
PY - 2010/4
Y1 - 2010/4
N2 - Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The median CD4+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
AB - Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The median CD4+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
KW - Chemotherapy
KW - FOLFOX4
KW - HAART
KW - HIV-infection
KW - Metastatic colorectal cancer
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=77954050860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954050860&partnerID=8YFLogxK
U2 - 10.2174/157016210791111061
DO - 10.2174/157016210791111061
M3 - Article
C2 - 20158458
AN - SCOPUS:77954050860
VL - 8
SP - 218
EP - 222
JO - Current HIV Research
JF - Current HIV Research
SN - 1570-162X
IS - 3
ER -